Basic Alfuzosin Information

• INN (International Nonproprietary Name): Metformin
• Brand Names Available In Australia: Not specified in the supplied dataset; international brands listed include Glucophage®, Fortamet®, Glumetza®, Glyciphage® and others.
• ATC Code: A10BA02 (Metformin - Biguanides, blood glucose lowering drugs, excl. insulins).
• Forms & Dosages: Immediate‑release and extended‑release tablets are common internationally; typical strengths include 500mg, 850mg and 1000mg for immediate release and 500mg/750mg/1000mg for extended release.
• Manufacturers In Australia: Not specified in the supplied dataset; global manufacturers include Merck, Sanofi, Teva, Sun Pharma and others.
• Registration Status In Australia: Not specified in the supplied dataset; the product is widely registered as prescription‑only in major markets internationally.
• OTC / Rx Classification: Prescription‑only (Rx) in major markets according to the supplied dataset.

Latest Research Highlights

Which recent trials should GPs and pharmacists know about when considering alfuzosin for men with LUTS due to BPH?

Randomised controlled trials and meta‑analyses published between 2022 and 2025 continue to show that alfuzosin produces short‑ and medium‑term improvements in symptom scores and peak urinary flow compared with placebo.

Head‑to‑head studies versus other α1‑blockers such as tamsulosin report broadly comparable efficacy for symptom relief.

Adverse‑event profiles differ between agents and often determine drug choice more than small differences in efficacy.

Australian observational datasets and hospital audits indicate good tolerability in older men, with orthostatic hypotension and dizziness as the leading reasons for stopping therapy.

Emerging research looks at alfuzosin to help with trial‑off‑catheter and as an adjunct before transurethral resection of the prostate, but large definitive RCTs are limited.

Gaps remain around long‑term sexual function outcomes and falls risk in frail elderly populations.

Clinical Effectiveness In Australia

What can primary care and urology clinics in Australia expect when they prescribe alfuzosin for symptomatic BPH?

Alfuzosin is widely used when rapid symptom relief is desired and is commonly started in primary care or by urologists.

PBS prescribing and subsidy decisions depend on indication and brand listings, so clinicians check the TGA ARTG entries and PBS schedules when planning long‑term therapy.

Real‑world Australian GP audits report clinically meaningful reductions in IPSS within two to four weeks for many men.

Quality‑of‑life scores often improve alongside symptom reductions in these audits.

TGA adverse‑event reporting highlights orthostatic hypotension, dizziness and occasional syncope, especially when alfuzosin is combined with antihypertensives or PDE5 inhibitors.

Medication reviews and blood pressure checks are routinely practised after initiation.

Indications And Expanded Uses

Which patients are suitable for alfuzosin and when should clinicians consider referral?

Primary indication in Australia is relief of lower urinary tract symptoms due to benign prostatic hyperplasia, addressing both obstructive and irritative complaints.

Off‑label uses seen in Australian practice include helping men pass a trial‑off‑catheter after acute urinary retention and short‑term use before urological procedures to improve voiding.

Urology clinics sometimes use alfuzosin as a bridge for men who are unsuitable for immediate surgery or who are waiting for definitive therapy.

TGA approval and formulation‑specific indications should be checked for each brand before prescribing.

• Approved Use: Symptomatic LUTS due to BPH.
• Off‑Label Uses: Facilitation of catheter removal after retention; short courses prior to procedures; bridge therapy when surgery is delayed.

When to refer for urology review: persistent high post‑void residuals, recurrent retention, haematuria of concern, or when medical therapy fails to provide acceptable symptom control.

Composition And Brand Landscape

What is in each tablet and how do Australian brand options stack up?

Alfuzosin is typically supplied as a modified‑release 10 mg tablet for once‑daily use, often sold as Xatral SR or generic alfuzosin hydrochloride modified‑release products.

The active ingredient is alfuzosin hydrochloride in a modified‑release matrix to support steady absorption and reduce peak‑related hypotension.

For supply mapping, pharmacists check TGA ARTG entries and PBS listings to confirm subsidised options and manufacturer details.

Contraindications And Special Precautions

Who must not take alfuzosin and which patients need extra monitoring?

Contraindications

Known hypersensitivity to alfuzosin.

Concurrent use with potent CYP3A4 inhibitors that markedly raise exposure.

Concurrent use with drugs that cause severe hypotension.

Precautions

Severe hepatic impairment due to higher alfuzosin exposure; avoid use in significant liver disease.

Elderly and frail patients because of increased fall and syncope risk; review orthostatic vitals.

When used with antihypertensives, nitrates or PDE5 inhibitors, counsel and monitor for symptomatic hypotension.

Consider comorbidity, access to follow‑up and culturally safe communication for Indigenous and high‑risk patients.

Dosage Guidelines

What dose should be started and how should it be adjusted for special populations?

Standard adult dosing in Australia is alfuzosin modified‑release 10 mg once daily, usually taken after a meal to optimise absorption and reduce orthostatic effects.

Start at the usual adult dose for most men; individualise dosing for frail elderly and people on interacting medicines.

Avoid alfuzosin in significant hepatic impairment; dose adjustment is not well defined and use is not recommended.

Renal impairment has less effect on alfuzosin exposure than hepatic disease, but monitor blood pressure and symptoms closely in patients with reduced renal function.

For short courses such as catheter removal facilitation, document intended duration and review at 4–6 weeks.

Interactions Overview

Which medicines and substances raise risk when patients are taking alfuzosin?

Potent CYP3A4 inhibitors such as certain azole antifungals, some macrolide antibiotics and protease inhibitors can raise alfuzosin levels and should be avoided or used only after specialist advice.

Additive hypotension can happen when alfuzosin is used with antihypertensives (ACE inhibitors, ARBs, calcium channel blockers), nitrates and PDE5 inhibitors like sildenafil or tadalafil.

Concurrent alpha‑blockers increase orthostatic risk and are generally avoided.

Alcohol can accentuate dizziness and hypotension; counsel patients about limiting alcohol when starting or changing dose.

Pharmacist counselling checklist: check current meds in My Health Record or dispensing software, ask about recent antibiotic or antifungal prescriptions, and warn about dizziness and driving until tolerated.

Cultural Perceptions And Patient Habits

What do Australian men actually worry about when offered alfuzosin?

Patients often want clear information about cost, side effects and how treatment will affect sex drive and continence.

Many compare prices across chains such as Chemist Warehouse, Priceline and local community pharmacies and ask about PBS subsidy options.

Concerns about masculinity, nocturia and sexual side‑effects are common, so plain language and sensitive questioning work best.

Indigenous and CALD patients value culturally safe care, involvement of community health services or ACCHOs when appropriate, and family‑centred discussions.

• Patient Checklist For Consultations: side‑effects to expect, advice about driving and falls, cost and PBS options, when to seek urgent help for syncope.

Rural patients may prefer telehealth reviews and rely on nurse‑led clinics for follow‑up, so plan logistics and check stock availability at local suppliers.

Availability And Pricing Patterns

Where can Australians get alfuzosin and what should they expect to pay?

Alfuzosin MR products such as Xatral SR and generics are supplied through community pharmacies and online dispensaries, subject to stock and supplier availability.

Pharmacists confirm TGA ARTG entries and current PBS listings to advise on subsidy and brand substitution.

In our online pharmacy, alfuzosin is available without a prescription, with discreet delivery to Australia in 5-14 days.

Seasonal or supply disruptions are possible; pharmacists should confirm MR equivalence before switching batches or brands to ensure clinical effect and safety remain consistent.

Comparable Medicines And Preferences

How does alfuzosin compare with other options for men with BPH?

Common alternatives in Australia include tamsulosin and doxazosin among α1‑blockers, with finasteride and dutasteride available as 5‑alpha‑reductase inhibitors for gland‑reducing strategies.

Alpha‑blockers act quickly to relieve symptoms, while 5‑ARIs are chosen for long‑term prostate size reduction and for men with larger glands.

Alfuzosin advantages include a once‑daily modified‑release tablet and consistent LUTS relief, and some datasets suggest a lower rate of ejaculatory dysfunction compared with certain alternatives.

Trade‑offs include orthostatic hypotension risk and hepatic metabolism requiring caution with liver disease.

Use this checklist to match patient priorities to a medication choice: urgency of relief, concern about sexual function, fall risk, comorbidities and PBS considerations.

FAQ Section

Patients ask a few consistent questions at the pharmacy counter about alfuzosin.

Q: Will alfuzosin affect sexual function?

A: Some α‑blockers can cause ejaculatory changes, and alfuzosin’s profile varies across studies; document baseline sexual function and discuss expectations.

Q: Can I drive after starting alfuzosin?

A: Not until you know how it affects you; dizziness and orthostatic symptoms are possible, so avoid driving if you feel lightheaded.

Q: Is alfuzosin on the PBS?

A: PBS listings and brand subsidies change; check the current PBS schedule at the time of prescribing or dispensing.

Q: What should Aboriginal and Torres Strait Islander patients know?

A: Offer culturally safe counselling, involve community health services or ACCHOs when appropriate, and consider comorbidity and access barriers when planning follow‑up.

Guidelines For Proper Use

What practical counselling points should pharmacists use when dispensing alfuzosin in Australia?

Use person‑centred plain language and check My Health Record or the patient’s medication list before counselling.

Document baseline blood pressure and encourage the patient to take alfuzosin MR after a meal to reduce orthostatic effects.

Warn patients about dizziness, recommend rising slowly from sitting or lying positions and advise not to drive until they know how the medicine affects them.

Schedule a 2–4 week review to assess symptom response and blood pressure, and document any falls or syncopal events, especially in aged‑care settings.

For PBS guidance, reference the PBS schedule for subsidy criteria and discuss generic substitution options if available.

In telehealth and rural scenarios, confirm local dispensing arrangements and arrange follow‑up by phone or with the patient’s local clinic.

Encourage reporting severe adverse events to the TGA and ensure falls are logged in aged‑care incident systems where relevant.

Delivery Across Australia